Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction

Gondi N. Kumar, Jennifer Dykstra, Ellen M. Roberts, Venkata K. Jayanti, Dean Hickman, John Uchic, Ye Yao, Bruce Surber, Samuel Thomas and G. Richard Granneman
Drug Metabolism and Disposition August 1999, 27 (8) 902-908;
Gondi N. Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Dykstra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen M. Roberts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkata K. Jayanti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean Hickman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Uchic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ye Yao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Surber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Richard Granneman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

ABT-378 is a potent in vitro inhibitor of the HIV protease and is currently being developed for coadministration with another HIV protease inhibitor, ritonavir, as an oral therapeutic treatment for HIV infection. In the present study, the effect of ritonavir, a potent inhibitor of cytochrome P-450 (CYP) 3A, on the in vitro metabolism of ABT-378 was examined. Furthermore, the effect of ABT-378-ritonavir combinations on several CYP-dependent monooxygenase activities in human liver microsomes was also examined. ABT-378 was found to undergo NADPH- and CYP3A4/5-dependent metabolism to three major metabolites, M-1 (4-oxo) and M-3/M-4 (4-hydroxy epimers), as well as several minor oxidative metabolites in human liver microsomes. The mean apparent Km andVmax values for the metabolism of ABT-378 by human liver microsomes were 6.8 ± 3.6 μM and 9.4 ± 5.5 nmol of ABT-378 metabolized/mg protein/min, respectively. Ritonavir inhibited human liver microsomal metabolism of ABT-378 potently (Ki = 0.013 μM). The combination of ABT-378 and ritonavir was much weaker in inhibiting CYP-mediated biotransformations than ritonavir alone, and the inhibitory effect appears to be primarily due to the ritonavir component of the combination. The ABT-378-ritonavir combinations (at 3:1 and 29:1 ratios) inhibited CYP3A (IC50 = 1.1 and 4.6 μM), albeit less potently than ritonavir (IC50 = 0.14 μM). Metabolic reactions mediated by CYP1A2, CYP2A6, and CYP2E1 were not affected by the ABT-378-ritonavir combinations. The inhibitory effects of ABT-378-ritonavir combinations on CYP2B6 (IC50 = >30 μM), CYP2C9 (IC50 = 13.7 and 23.0 μM), CYP2C19 (IC50 = 28.7 and 38.0 μM), and CYP2D6 (IC50 = 13.5 and 29.0 μM) were marginal and are not likely to produce clinically significant drug-drug interactions.

Footnotes

  • Send reprint requests to: Dr. G. Richard Granneman, Clinical Pharmacokinetics and Toxicokinetics, AP-13A, Abbott Laboratories, Abbott Park, IL 60064. E-mail:rick.g.granneman{at}abbott.com

  • ↵1 J.D. was a recipient of an Abbott Summer (1996) Research Internship.

  • Abbreviations used are::
    CYP
    cytochrome P-450
    AUC
    area under the curve
    Cmax
    maximal plasma concentration
    • Received January 29, 1999.
    • Accepted May 6, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (8)
Drug Metabolism and Disposition
Vol. 27, Issue 8
1 Aug 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction

Gondi N. Kumar, Jennifer Dykstra, Ellen M. Roberts, Venkata K. Jayanti, Dean Hickman, John Uchic, Ye Yao, Bruce Surber, Samuel Thomas and G. Richard Granneman
Drug Metabolism and Disposition August 1, 1999, 27 (8) 902-908;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction

Gondi N. Kumar, Jennifer Dykstra, Ellen M. Roberts, Venkata K. Jayanti, Dean Hickman, John Uchic, Ye Yao, Bruce Surber, Samuel Thomas and G. Richard Granneman
Drug Metabolism and Disposition August 1, 1999, 27 (8) 902-908;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • High-throughput Characterization of SLCO1B1 Variants of VUS.
  • Poria cocos triterpenes as bile acid transporter inhibitors
  • Clearance pathways: fevipiprant with probenecid perpetrator
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics